



## Management Change

April 18, 2024

RNS Number : 0516L

Renalytix PLC

18 April 2024

**Renalytix plc**  
**("Renalytix" or the "Company")**

**Renalytix Announces Management Change - Howard Doran Promoted to President**

**LONDON and SALT LAKE CITY, 18 April 2024** - [Renalytix plc](#) (NASDAQ: RNLX) (LSE: RENX) announces that Howard Doran, who has served as the Company's Chief Business Officer since September 2023, has been appointed as President, effective April 30, 2024. Thomas McLain, who has served as the Company's President since July 2019, is stepping down effective that date.

**James McCullough, Renalytix CEO, said:**

*"We thank Tom for his many accomplishments in helping Renalytix achieve the tri-fecta of broad insurance coverage, FDA regulatory approval and real-world outcomes evidence that now positions KidneyIntelX for commercial adoption.*

*"Howard assumes the position of President to lead the global sales effort having now built our sales team from individuals with leading industry sales track records."*

For further information, please contact:

**Renalytix plc**

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

**Stifel (Nominated Adviser to the Company)**

Nicholas Moore / Alex Price / Nick Harland / Samira  
Essebiya / Harry Billen

**Tel: 02077107600**

**Investec Bank plc**

Gary Clarence / Shalin Bhamra

**Tel: 020 7597 4000**

**Walbrook PR Limited**

Paul McManus / Alice Woodings / Charlotte Edgar

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

**CapComm Partners**

Peter DeNardo

**Tel: 415-389-6400** or [investors@renalytix.com](mailto:investors@renalytix.com)

**About Renalytix**

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCIRMTTMTTBTRI